论文部分内容阅读
目的分析普萘洛尔治疗肝硬化门静脉高压症的临床效果。方法选取漯河市郾城区中医院2013年1月—2014年1月收治的肝硬化门静脉高压症患者80例,按照随机数字表法分为观察组与对照组,每组40例。两组患者均给予基础治疗,观察组口服普萘洛尔,对照组口服5-单硝酸异山梨酯,观察两组患者门静脉血流量、脾静脉血流量及总胆红素(TBi L)、清蛋白(ALB)、丙氨酸氨基转移酶(ALT)水平。结果治疗前两组患者门静脉、脾静脉血流量比较,差异无统计学意义(P>0.05);治疗后两组患者门静脉、脾静脉血流量均低于治疗前,差异有统计学意义(P<0.05),且观察组门静脉、脾静脉血流量低于对照组,差异有统计学意义(P<0.05)。观察组TBi L、ALB、ALT低于对照组,差异有统计学意义(P<0.05)。结论普萘洛尔治疗肝硬化门静脉高压症效果显著,可有效降低患者门静脉、脾静脉血流量,进而降低门静脉、脾静脉压力及TBi L、ALB及ALT水平。
Objective To analyze the clinical effect of propranolol in the treatment of liver cirrhosis and portal hypertension. Methods Eighty patients with cirrhosis and portal hypertension who were admitted to Tangcheng Hospital of Traditional Chinese Medicine from January 2013 to January 2014 in Luohe were randomly divided into observation group and control group according to the random number table method, with 40 cases in each group. Patients in both groups were treated with propranolol orally and oral 5-isosorbide mononitrate in the control group. The portal vein blood flow, splenic venous blood flow and total bilirubin (TBiL) Protein (ALB), alanine aminotransferase (ALT) levels. Results There was no significant difference in portal blood flow and splenic vein blood flow between the two groups before treatment (P> 0.05). The blood flow of portal vein and splenic vein in both groups after treatment was lower than that before treatment (P < 0.05). The blood flow in the portal vein and splenic vein in the observation group was lower than that in the control group (P <0.05). TBi L, ALB and ALT in the observation group were lower than those in the control group, with significant difference (P <0.05). Conclusion Propranolol is effective in treating cirrhotic portal hypertension, which can effectively reduce the portal vein and splenic vein blood flow, and then reduce the portal vein and splenic venous pressure and the levels of TBi L, ALB and ALT.